To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question

被引：0
|
作者：
Lukasik, Zuzanna [1 ,2 ]
Carron, Philippe [1 ,2 ]
Webers, Casper [3 ,4 ]
机构：
[1] Univ Ghent, Ghent Univ Hosp, Dept Internal Med & Pediat, Ghent, Belgium
[2] VIB Ctr Inflammat Res, Ghent, Belgium
[3] Maastricht Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Maastricht, Netherlands
[4] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands
来源：
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2023年 / 37卷 / 03期
关键词：
Axial spondyloarthritis; Tapering; Discontinuation; Remission; Therapy; Biological DMARD; SOCIETY CLASSIFICATION CRITERIA; ASAS-EULAR RECOMMENDATIONS; ANKYLOSING-SPONDYLITIS; PSORIATIC-ARTHRITIS; DOSE REDUCTION; PERIPHERAL SPONDYLOARTHRITIS; RHEUMATOID-ARTHRITIS; NON-INFERIORITY; TNF-INHIBITORS; DOUBLE-BLIND;
D O I：
10.1016/j.berh.2023.101869
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and discontinuation of bDMARDs in patients with axSpA. We discuss the scientific rationale and benefits of tapering, identify advice to apply tapering in current practice, and delineate aspects to be investigated in future research. (c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页数：17
相关论文
共 50 条
  • [41] Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis
    Kelly, Ayano
    Tymms, Kathleen
    Tunnicliffe, David J.
    Sumpton, Daniel
    Perera, Chandima
    Fallon, Kieran
    Craig, Jonathan C.
    Abhayaratna, Walter
    Tong, Allison
    ARTHRITIS CARE & RESEARCH, 2018, 70 (04) : 525 - 532
  • [42] A clinical and economic review of disease-modifying antirheumatic drugs
    Gabriel, SE
    Coyle, D
    Moreland, LW
    PHARMACOECONOMICS, 2001, 19 (07) : 715 - 728
  • [43] Conventional disease-modifying antirheumatic drugs in early arthritis
    Sokka, T
    Hannonen, P
    Möttönen, T
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2005, 31 (04) : 729 - +
  • [44] Putting new disease-modifying antirheumatic drugs into perspective
    Saseen, Joseph J.
    PHARMACOTHERAPY, 2007, 27 (12): : 1609 - 1610
  • [45] Perinatal Use and Discontinuation of Disease-Modifying Antirheumatic Drugs
    Rebic, Nevena
    De Vera, Mary A.
    Gupta, Amit
    Amiri, Neda
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2024, 30 (05) : 188 - 192
  • [46] Disease-modifying antirheumatic drugs: enhancing efficacy by combination
    Schnabel, A
    LANCET, 2004, 363 (9410): : 670 - 671
  • [47] Proposal for a new nomenclature of disease-modifying antirheumatic drugs
    Smolen, Josef S.
    van der Heijde, Desiree
    Machold, Klaus P.
    Aletaha, Daniel
    Landewe, Robert
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 3 - 5
  • [48] Safety overview of new disease-modifying antirheumatic drugs
    Cush, JJ
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2004, 30 (02) : 237 - +
  • [49] The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology
    Landewe, Robert B. M.
    LANCET RHEUMATOLOGY, 2021, 3 (04): : 306 - 312
  • [50] THE EFFECT OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS PATIENT REPORTED OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS; A SYSTEMATIC LITERATURE REVIEW AND A CALL FOR ACTION
    Rodrigues-Manica, S.
    Leite Silva, J.
    Machado, A. R.
    Coelho, C.
    Duarte, J.
    Vieira-Sousa, E.
    Tavares-Costa, J.
    Pimentel-Santos, F. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1550 - 1551
12345